BRISTOL-MYERS SQUIBB COMPANY Other Revenue, Net (Deprecated 2018-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Revenue, Net (Deprecated 2018-01-31) of $258.00 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.
Discontinued › Income Statement › Other Income
us-gaap:OtherSalesRevenueNet · last filed 2018-10-25
- BRISTOL-MYERS SQUIBB COMPANY other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-09-30 was $258.00M, a 34.18% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $243.00M, a 35.03% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $221.00M, a 36.68% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $403.00M, a 6.06% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other revenue, net (deprecated 2018-01-31) for fiscal 2017 was $1.52B, a 12.00% decline from fiscal 2016.
- BRISTOL-MYERS SQUIBB COMPANY other revenue, net (deprecated 2018-01-31) for fiscal 2016 was $1.73B, a 31.41% decline from fiscal 2015.
- BRISTOL-MYERS SQUIBB COMPANY other revenue, net (deprecated 2018-01-31) for fiscal 2015 was $2.52B, a 40.39% decline from fiscal 2014.
- BRISTOL-MYERS SQUIBB COMPANY other revenue, net (deprecated 2018-01-31) for fiscal 2014 was $4.22B, a 3.38% increase from fiscal 2013.
| Period end | Other Revenue, Net (Deprecated 2018-01-31) 3 month | Other Revenue, Net (Deprecated 2018-01-31) 6 month | Other Revenue, Net (Deprecated 2018-01-31) 9 month | Other Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-09-30 | $258.00M 10-Q · filed 2018-10-25 | $501.00M derived: sum of 2 quarters · filed 2018-10-25 | $722.00M 10-Q · filed 2018-10-25 | $1.13B derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-06-30 | $243.00M 10-Q · filed 2018-07-26 | $464.00M 10-Q · filed 2018-07-26 | $867.00M derived: sum of 3 quarters · filed 2018-07-26 | $1.26B derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-03-31 | $221.00M 10-Q · filed 2018-04-26 | $624.00M derived: sum of 2 quarters · filed 2018-04-26 | $1.02B derived: sum of 3 quarters · filed 2018-10-25 | $1.39B derived: sum of 4 quarters · filed 2018-10-25 |
| 2017-12-31 | $403.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $795.00M derived: sum of 2 quarters · filed 2018-10-25 | $1.17B derived: sum of 3 quarters · filed 2018-10-25 | $1.52B 10-K · filed 2018-02-13 |
| 2017-09-30 | $392.00M 10-Q · filed 2018-10-25 | $766.00M derived: sum of 2 quarters · filed 2018-10-25 | $1.11B 10-Q · filed 2018-10-25 | $1.54B derived: sum of 4 quarters · filed 2018-10-25 |
| 2017-06-30 | $374.00M 10-Q · filed 2018-07-26 | $723.00M 10-Q · filed 2018-07-26 | $1.15B derived: sum of 3 quarters · filed 2018-07-26 | $1.58B derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-03-31 | $349.00M 10-Q · filed 2018-04-26 | $778.00M derived: sum of 2 quarters · filed 2018-04-26 | $1.21B derived: sum of 3 quarters · filed 2018-04-26 | $1.65B derived: sum of 4 quarters · filed 2018-04-26 |
| 2016-12-31 | $429.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $859.00M derived: sum of 2 quarters · filed 2018-02-13 | $1.30B derived: sum of 3 quarters · filed 2018-02-13 | $1.73B 10-K · filed 2018-02-13 |
| 2016-09-30 | $430.00M 10-Q · filed 2017-10-26 | $869.00M derived: sum of 2 quarters · filed 2017-10-26 | $1.30B 10-Q · filed 2017-10-26 | $1.72B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $439.00M 10-Q · filed 2017-07-27 | $866.00M 10-Q · filed 2017-07-27 | $1.29B derived: sum of 3 quarters · filed 2018-02-13 | $1.81B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $427.00M 10-Q · filed 2017-04-27 | $852.00M derived: sum of 2 quarters · filed 2018-02-13 | $1.37B derived: sum of 3 quarters · filed 2018-02-13 | $1.96B derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $425.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $942.00M derived: sum of 2 quarters · filed 2018-02-13 | $1.53B derived: sum of 3 quarters · filed 2018-02-13 | $2.52B 10-K · filed 2018-02-13 |
| 2015-09-30 | $517.00M 10-Q · filed 2016-10-27 | $1.11B derived: sum of 2 quarters · filed 2016-10-27 | $2.09B 10-Q · filed 2016-10-27 | $3.11B derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $591.00M 10-Q · filed 2016-07-28 | $1.57B 10-Q · filed 2016-07-28 | $2.59B derived: sum of 3 quarters · filed 2017-02-21 | $3.67B derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $982.00M 10-Q · filed 2016-04-28 | $2.00B derived: sum of 2 quarters · filed 2017-02-21 | $3.08B derived: sum of 3 quarters · filed 2017-02-21 | $4.20B derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $1.02B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $2.10B derived: sum of 2 quarters · filed 2017-02-21 | $3.21B derived: sum of 3 quarters · filed 2017-02-21 | $4.22B 10-K · filed 2017-02-21 |
| 2014-09-30 | $1.08B 10-Q · filed 2015-10-27 | $2.20B derived: sum of 2 quarters · filed 2015-10-27 | $3.20B 10-Q · filed 2015-10-27 | $4.34B derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $1.12B 10-Q · filed 2015-07-23 | $2.12B 10-Q · filed 2015-07-23 | $3.27B derived: sum of 3 quarters · filed 2016-02-12 | $4.31B derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $1.00B 10-Q · filed 2015-04-28 | $2.15B derived: sum of 2 quarters · filed 2016-02-12 | $3.19B derived: sum of 3 quarters · filed 2016-02-12 | $4.21B derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $1.14B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $2.18B derived: sum of 2 quarters · filed 2016-02-12 | $3.21B derived: sum of 3 quarters · filed 2016-02-12 | $4.08B 10-K · filed 2016-02-12 |
| 2013-09-30 | $1.04B 10-Q · filed 2014-10-24 | $2.06B derived: sum of 2 quarters · filed 2014-10-24 | $2.94B 10-Q · filed 2014-10-24 | |
| 2013-06-30 | $1.02B 10-Q · filed 2014-07-24 | $1.90B 10-Q · filed 2014-07-24 | ||
| 2013-03-31 | $874.00M 10-Q · filed 2014-04-29 | |||
| 2012-12-31 | $3.97B 10-K · filed 2015-02-13 | |||
| 2011-12-31 | $3.62B 10-K · filed 2014-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |